Tag: Johnson & Johnson

  • Affordable TB Medicines: South Africa’s Patent Battle

    South Africa’s battle for affordable TB medicines echoes the country’s earlier struggle to expand access to HIV treatment. During the late 1990s and early 2000s, South Africa faced an uncontrolled AIDS epidemic. The crisis was worsened by the government’s rejection of the scientific consensus on HIV/AIDS. Under former President Thabo Mbeki, many public-sector patients were denied access to life-saving antiretroviral…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Competition Commission and J&J reach TB drug agreement

    The Competition Commission has reached a landmark agreement with Johnson & Johnson (J&J) and its subsidiary, Janssen Pharmaceuticals, under which J&J will not enforce its patent on a crucial tuberculosis (TB) drug in 134 low- and middle-income countries. Additionally, J&J will reduce the drug’s price for South Africa’s Department of Health by approximately 40%. This decision not to enforce the…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in